HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?

Abstract
Patients who are at high or very high risk for atherosclerotic cardiovascular disease (ASCVD) events derive the greatest benefit when clinicians prescribe evidence-based preventive therapies. The writing process used in the creation of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol employed a thorough evaluation of the highest quality evidence, and synthesis of this evidence into actionable recommendations for ASCVD risk reduction. Clinical trials supporting the addition of ezetimibe, PCSK9 inhibitors, or both to evidence-based statins provide the basis for the updated recommendations for the preventive care of these patients. The publication in late 2018 of a randomized controlled trial supporting the net ASCVD risk reduction benefit of adding icosapent ethyl to statins in selected hypertriglyceridemic patients with clinical ASCVD and/or type 2 diabetes with multiple additional risk markers provides the rationale for incorporation of icosapent ethyl therapy into future ASCVD preventive care regimens.
AuthorsCarl E Orringer
JournalTrends in cardiovascular medicine (Trends Cardiovasc Med) Vol. 30 Issue 3 Pg. 151-157 (04 2020) ISSN: 1873-2615 [Electronic] United States
PMID31101399 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.
Chemical References
  • Biomarkers
  • Hypolipidemic Agents
  • Lipids
  • eicosapentaenoic acid ethyl ester
  • Eicosapentaenoic Acid
Topics
  • Adult
  • Aged
  • Atherosclerosis (blood, diagnosis, epidemiology, prevention & control)
  • Biomarkers (blood)
  • Clinical Decision-Making
  • Consensus
  • Dyslipidemias (blood, diagnosis, drug therapy, epidemiology)
  • Eicosapentaenoic Acid (adverse effects, analogs & derivatives, therapeutic use)
  • Evidence-Based Medicine (standards)
  • Female
  • Humans
  • Hypolipidemic Agents (adverse effects, therapeutic use)
  • Lipids (blood)
  • Male
  • Middle Aged
  • Practice Guidelines as Topic (standards)
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: